* drugs
** isoniazid
*** mechanism of action
Block synthesis of mycolic acids
*** [#B] adverse effects
peripheral neuropathy
*** warnings
- hepatotoxicity
- hypersensitivity
  - rash
  - drug fever
*** pharmacokinetics
- inhibitor of 2C9
- inhibitor of 2C19
*** [#B] drug interactions
warfarin
*** indications
- active TB
- latent TB
*** counseling
administer with vitamin B6 / pyridoxine
*** pharmacokinetics
- acetylated in liver
- slow acetylators (a small population in the USA) will have higher drug levels
** INH, Ethionamide
*** mechanism of action
Block synthesis of mycolic acids
*** target
acyl carrier protein, b-keto acyl carrier protein, FAS II
** Pyrazinamide
*** mechanism of action
- Inhibit cell membrane metabolism and transport functions
- bactericidal
- prodrug activated by acidic conditions
*** target
Fatty acid synthetase I (FAS I)??
*** drug interactions
- PPIs
- H2RAs
*** warnings
- hepatotoxicity
- hyperuricemia
- arthralgias
*** advantages
shortens duration of therapy from 9 months to 6 months
*** indication
only for initial 2 months of active disease
** Rifampin/rifapentin
*** mechanism of action
Inhibit RNA synthesis
*** target
RNA polymerase
*** indication
- latent TB
- active TB
*** warnings
- hepatotoxicity
- thrombocytopenia (at high dose)
*** pharmacokinetics
- CYP450 3A4 inducer
** Ethambutol
*** mechanism of action
- Inhibit cell wall synthesis (arabinogalactan)
- bacteriostatic
*** warnings
- optic neuritis---unable to differentiate red from green
- hypersensitivity
  - rash
  - drug fever
*** target
Arabynosyl transferase
*** unique
- renal dose adjustment
- bacteriostatic
** Streptomycin/kanamycin, Capreomycin, Amikacin
*** mechanism of action
Inhibit protein synthesis
*** target
30s ribosomal subunit
** Fluoroquinolones
*** mechanism of action
Inhibit DNA replication
*** target
Topoisomerase II and IV
** PAS, Dapsone
*** mechanism of action
Inhibit folate synthesis
*** target
Dihydropteroate synthase
** Clofazimine
*** mechanism of action
Inhibit transcription
*** target
DNA template
** Cycloserine
*** mechanism of action
Inhibit peptidoglycan synthesis
*** target
Alanine racemase (L-alanine to D-alanine)
** Bedaquiline
*** mechanism of action
Inhibits ATP synthesis
*** target
Proton pump 
*** indication
- MDR pulmonary TB
- only if no other effective treatment regimen is available
- use with ≥ 3 active TB drugs
*** black box warning
increased risk of death
* tuberculosis
** drug-sensitive
*** first line treatment
- isoniazid
- rifampin
- ethambutol
- pyrazinamide
*** second-line
- Aminoglycosides
  - Amikacin
  - Kanamycin
- Polypeptides: Capreomycin, Viomycin, Enviomycin
- Fluroquinolones: Ciprofloxacin, levofloxacin, moxifloxacin
- Thioamides: Ethionamide, prothionamide
- Rifamycin: Rifabutin (Ansamycin), Rifapentine
- Aminosalicyclic Acid (PAS)
- Cycloserine
** special populations
*** HIV/AIDS
- substitute rifabutin instead of rifampin
- don’t use highly intermittent regimens
*** hepatic failure
**** symptoms
- transaminases >5x ULN
  - ALT
  - AST
- total billirubin >3
- nausea, vomiting, jaundice
**** liver sparing regimen
- streptomycin
- levofloxacin
- ethambutol
**** strategy
Sequential reintroduction with frequent testing of liver enzymes to identify the offending agent
*** pregnancy
**** not recommended
pyrazinamide
**** recommended
for 9 months...
- rifampin
- isoniazid
- ethambutol
*** renal insufficiency
- ethambutol
- pyrazinamide
- aminoglycoside
* [#A] drugs to supplement with pyridoxine
- isoniazid
- cycloserine
- ethambutol
* prodrugs
- pyrazinamide
* drugs with toxicity
** hepatotoxicity
- rifampin
- isoniazid
- pyrazinamide
** nephrotoxicity
- ethambutol
** neuropathy
*** mitigation
supplementation with vitamin B6
*** [#B] drugs
- isoniazid
- cycloserine
- ethionamide
* TODO memorize slide 21/46 Tuberculosis Cates
